# US 7,411,043 B2 · Slo4 potassium channel proteins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,411,043 B2
- Document ID: US7411043B2
- Status: Granted
- Kind: B2
- Application number: 11/325,764
- Filed: 2006-01-04
- Published: 2006-05-11
- Granted: 2008-08-12
- Earliest claimed: 2000-11-15
- Assignees: Icagen, Inc.
- Inventors: Timothy James Jegla; Julie Dickson Witzel
- Web page: https://patentgrep.com/patent/US7411043B2

## CPC

- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- A61P 25/02: for peripheral neuropathies
- A61P 25/06: Antimigraine agents
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides isolated nucleic acid and amino acid sequences of Slo2 and Slo4, members of the Slo family of potassium channel proteins, also known as “maxi” or BK potassium channel proteins. Also provided herein are antibodies to Slo2 and Slo 4, methods of detecting Slo2 and Slo 4, methods of screening for potassium channel activators and inhibitors using biologically active Slo2 and Slo 4, and kits for screening for activators and inhibitors of voltage-gated potassium channels comprising Slo2 and Slo 4.

## Claims

### Claim 1

An isolated Slo4 polypeptide comprising an alpha subunit of a Slo potassium channel, the polypeptide:
(i) forming, with at least one additional alpha subunit, a potassium channel comprising the characteristic of voltage-gating; and
(ii) comprising an amino acid sequence having at least 80% identity to SEQ ID NO:4.

### Claim 2 (depends on 1)

The polypeptide of claim 1, wherein the polypeptide specifically binds to antibodies generated against SEQ ID NO:4.

### Claim 3 (depends on 1)

The polypeptide of claim 1, wherein the potassium channel further comprises the characteristic of rapid activation.

### Claim 4 (depends on 1)

The polypeptide of claim 1, wherein the polypeptide has a molecular weight of between about 134 kD to about 144 kD.

### Claim 5 (depends on 1)

The polypeptide of claim 1, wherein the polypeptide comprises an amino acid sequence of SEQ ID NO:4.

### Claim 6 (depends on 1)

The polypeptide of claim 1, wherein the polypeptide comprises an alpha subunit of a homomeric potassium channel.

### Claim 7 (depends on 1)

The polypeptide of claim 1, wherein the polypeptide comprises an alpha subunit of a heteromeric potassium channel.

### Claim 8 (depends on 1)

The polypeptide of claim 1, wherein the polypeptide comprises a sequence having at least 90% identity to SEQ ID NO:4.